Detail akcie IO Biotech Rg online

Business Summary: IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Financial Summary: BRIEF: For the six months ended 30 June 2025, IO Biotech Inc revenues was not reported. Net loss increased 21% to $48.6M. Higher net loss reflects Pharmaceutical segment loss increase from $20.2M to $45.8M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.61 to -$0.74.